drugset
drugset / Trial / NCT02736656

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

NCT02736656 ↗

Phase 3 Active not recruiting 1400 enrolled Supernus Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients

Timeline

Start
2016-02-02
Primary completion
2026-09
Completion
2026-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Viloxazine Small molecule 100 mg Oral
Subject Viloxazine Small molecule 400 mg Oral
Subject Viloxazine Small molecule 600 mg Oral

Indications

attention deficit-hyperactivity disorder